http://www.healio.com/pediatrics/influenza/news/online/%7B1bd566a8-d82d-4db5-bc63-4d99d27aec2b%7D/quadrivalent-influenza-vaccine-shows-superior-immunogenicity-vs-trivalent-vaccine-in-young-children
Posted by Rob Lambkin-Williams
hVIVO is the new name of Retroscreen Virology! (from 15 April 2015). hVIVO is a rapidly growing UK life sciences company pioneering a technology platform which uses human challenge models of disease involving healthy volunteers to study new drugs and investigate disease in a safe, controlled, clinical environment. Our belief is that the best way to understand human disease is by studying it in humans, not laboratory models.
No comments:
Post a Comment